The earnings call highlighted several positive developments, including revenue growth, cost control, and significant milestones in product development. However, challenges such as a net loss and decreased cash reserves present concerns. Despite these challenges, the overall sentiment leans positive due to the strong operational achievements and strategic advancements.

Company Guidance

During the first quarter of fiscal year 2025, Biofrontera achieved significant financial progress with total revenues reaching $8.6 million, marking a 9% increase from the previous year. The company reported a reduction in total operating expenses to $13.1 million, down from $13.4 million in the prior year, and a decrease in cost of revenues from $4.0 million to $3.1 million. Despite incurring a net loss of $4.2 million, this was a substantial improvement compared to the $10.4 million loss in the first quarter of 2024. Biofrontera's adjusted EBITDA increased from $4.6 million to $4.4 million, driven by a $1.5 million increase in gross profit. The company also noted a reduction in SG&A expenses by 6.5% and increased R&D expenses by $1.2 million, reflecting its strategic focus on clinical trials and cost management. Looking forward, Biofrontera aims to maintain revenue growth and achieve record revenues in 2025 without increasing costs, while its current cash position stands at $1.8 million.

Revenue Growth

Total revenues for the first quarter of 2025 were $8.6 million, a 9% increase compared to the same period in the prior year.

Cost Control and Efficiency

Cost of revenue and operating costs were lower than the same period of the previous year. Cost of revenues decreased by 22.1%, and SG&A expenses decreased by 6.5%.

Patent and Product Development

A new formulation of Ameluz received patent protection until December 2043. The company is also advancing clinical trials for expanding the use of Ameluz.

Operational Milestones

Enrollment of the final patient in a Phase III clinical trial for Ameluz and completion of a key milestone in another Phase III study.

Profit and EBITDA Improvement

Gross profit increased, and adjusted EBITDA improved, driven by reduced cost structure and increased sales.

Biofrontera (GB:0DOL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:0DOL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Jun 03, 2026	2026 (Q1)	- / -	―	―	―	―
May 28, 2025	2025 (Q1)	- / -	―	―	―	―
Apr 24, 2025	2024 (Q4)	- / -	―	―	―	―
Aug 28, 2024	2024 (Q2)	- / -	0.063	―	―	―
May 31, 2024	2024 (Q1)	- / -	-0.664	―	―	―
Apr 30, 2024	2023 (Q4)	- / -0.52	-0.664	21.99% (+0.15)	―	―
Nov 15, 2023	2023 (Q3)	- / -	―	―	―	―
Aug 31, 2023	2023 (Q2)	- / 0.06	-1.778	103.54% (+1.84)	―	―
May 31, 2023	2023 (Q1)	- / -	-5.781	―	―	―
Apr 27, 2023	2022 (Q4)	- / -0.66	-5.781	88.51% (+5.12)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:0DOL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 28, 2025	€14.30	€14.30	0.00%
Apr 24, 2025	€14.30	€14.30	0.00%
Aug 28, 2024	€14.30	€14.30	0.00%
May 31, 2024	€14.30	€14.30	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Biofrontera AG (GB:0DOL) report earnings?

Biofrontera AG (GB:0DOL) is schdueled to report earning on Jun 03, 2026, TBA (Confirmed).

What is Biofrontera AG (GB:0DOL) earnings time?

Biofrontera AG (GB:0DOL) earnings time is at Jun 03, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Biofrontera AG stock?

The P/E ratio of Biofrontera is N/A.

What is GB:0DOL EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing